Cytokinetics (FRA:KK3A) Dividends per Share : €0.00 (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Dividends per Share?

Cytokinetics's dividends per share for the three months ended in Mar. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Cytokinetics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Cytokinetics Dividends per Share Historical Data

The historical data trend for Cytokinetics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Dividends per Share Chart

Cytokinetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Cytokinetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cytokinetics's Dividends per Share

For the Biotechnology subindustry, Cytokinetics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytokinetics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Dividend Yield % falls into.

Cytokinetics Dividends per Share Calculation

Dividends paid to per common share.

Cytokinetics (FRA:KK3A) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Cytokinetics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-1.224
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Cytokinetics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytokinetics (FRA:KK3A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (FRA:KK3A) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

CYTK:USA

Address

350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.cytokinetics.com

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics (FRA:KK3A) Headlines

No Headlines